Literature DB >> 28028622

Market approval for drugs in the EU: time to change direction?

Alessandro Curto1, Katelijne van de Vooren1, Livio Garattini2.   

Abstract

Mesh：

Year:  2017        PMID： 28028622     DOI： 10.1007/s10198-016-0863-5

Source DB:  PubMed          Journal:  Eur J Health Econ        ISSN： 1618-7598


× No keyword cloud information.
  3 in total

1.  Pharmaceutical Price Schemes in Europe: Time for a 'Continental' One?

Authors:  Livio Garattini; Alessandro Curto; Nick Freemantle
Journal:  Pharmacoeconomics       Date:  2016-05       Impact factor: 4.981

2.  The European Medicines Agency is still too close to industry.

Authors:  Silvio Garattini
Journal:  BMJ       Date:  2016-05-06

3.  European Medicines Agency: leave the UK but remain the same.

Authors:  Livio Garattini; Alessandro Curto
Journal:  J R Soc Med       Date:  2016-09       Impact factor: 5.344
  3 in total
  3 in total

1.  HTA for pharmaceuticals in Europe: will the mountain deliver a mouse?

Authors:  Livio Garattini; Anna Padula
Journal:  Eur J Health Econ       Date:  2020-02

2.  Comment on: 'NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence'.

Authors:  Livio Garattini; Nicholas Freemantle
Journal:  Pharmacoeconomics       Date:  2020-01       Impact factor: 4.981

3.  How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation.

Authors:  Anthony James Hatswell
Journal:  Ecancermedicalscience       Date:  2017-06-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.